ClinicalTrials.gg

Program

JSKN016HC

A development code.

Its studies are led by Alphamab Oncology.

Furthest: phase 1, since Mar 9, 20261 company-led study, 1 open or runningNext primary completion: Jul 1, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Alphamab Oncology11 open or runningphase 1since Mar 9, 2026Mar 9, 2026Jul 1, 2028phase 1 · NCT07475559

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 9, 2026First study: phase 1 study in Advanced Solid Tumor MalignanciesFirst studyNCT07475559 · 42 planned · Australia

Ahead

  1. Jul 1, 2028Primary completion: phase 1 study in Advanced Solid Tumor MalignanciesNCT07475559

TargetBeta

“JSKN016HC is a subcutaneously injectable formulation of a bispecific ADC targeting HER3 and TROP2 (the main active ingredient is JSKN016).”study text, by rule · the study

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
JSKN016ruleAlphamab Oncologyphase 35

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07475559Advanced Solid Tumor Malignancies · Australia1Not yet recruitingJul 1, 202842

How it is read

Names in the registry

  • “JSKN016HC”, 1 entry

Codes read as this program: JSKN016HC.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.